QLife (QLIFE) Q2 2025 earnings summary

Executive summary

• Entered a letter of intent for a reverse takeover merger with Hipro Biotechnology, valuing the combined entity at USD 90 million, aiming to lead in at-home diagnostics and direct-to-patient healthcare.

• Strategic roadmap updated to focus on commercialization, regulatory milestones, and partnerships in the fast-growing at-home diagnostics market.

• Clinical study for Egoo PHE self-test for children and youth completed with positive results, advancing toward regulatory approval in the UK and EU.

Financial highlights

• Q2 2025 revenue was KSEK 104, up from KSEK 39 in Q2 2024, driven by sales of Egoo.Health devices and capsules.

• EBITDA for Q2 2025 was KSEK -4,899, an improvement from KSEK -8,002 in Q2 2024; net loss narrowed to KSEK -5,174 from KSEK -12,979.

• Cash flow for Q2 2025 was KSEK -2,056, compared to KSEK -4,288 in Q2 2024; cash reserves at period end were KSEK 651.

• Earnings per share for Q2 2025 were SEK -0.62, compared to SEK -0.01 in Q2 2024.

Outlook and guidance

• Both parties remain committed to completing the merger, with the Share Purchase Agreement expected to be signed before year-end, pending regulatory approvals in China.

• Pilot projects with hospitals and pharmacies in Denmark are planned for autumn, targeting expanded product solutions and integration with public healthcare systems.

• Ongoing discussions with major pharmaceutical and distribution partners to expand direct-to-patient solutions globally.